Back تيغيسيكلين Arabic Tigecyklin Czech Tigecyclin German Tigeciclina Spanish تیگسایکلین Persian Tigesykliini Finnish Tigécycline French טיגציקלין HE Tigeciklin Hungarian Tigesiklin ID
 | |
| Clinical data | |
|---|---|
| Pronunciation | /ˌtaɪɡəˈsaɪkliːn/ |
| Trade names | Tygacil |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614002 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Intravenous (IV) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 71–89% |
| Metabolism | Not metabolized |
| Elimination half-life | 42.4 hours |
| Excretion | 59% Bile duct, 33% kidney |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.211.439 |
| Chemical and physical data | |
| Formula | C29H39N5O8 |
| Molar mass | 585.658 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections.[3][6][7] It is a glycylcycline class drug that is administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli.[6] As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.
It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on 17 June 2005.[6][7] It was approved for medical use in the European Union in April 2006.[4]
It was removed from the World Health Organization's List of Essential Medicines in 2019.[8][9] The World Health Organization classifies tigecycline as critically important for human medicine.[10]
- ^ "Tigecycline (Tygacil) Use During Pregnancy". Drugs.com. 6 July 2020. Retrieved 26 September 2020.
- ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
- ^ a b "Tygacil- tigecycline injection, powder, lyophilized, for solution". DailyMed. 20 July 2020. Retrieved 26 September 2020.
- ^ a b "Tygacil EPAR". European Medicines Agency (EMA) (in Aragonese). 17 September 2018. Retrieved 26 September 2020.
- ^ "EP2181330". European Patent Office. Retrieved 29 September 2017.
- ^ a b c Rose WE, Rybak MJ (August 2006). "Tigecycline: first of a new class of antimicrobial agents". Pharmacotherapy. 26 (8): 1099–1110. doi:10.1592/phco.26.8.1099. PMID 16863487. S2CID 29714610.
- ^ a b Kasbekar N (July 2006). "Tigecycline: a new glycylcycline antimicrobial agent". American Journal of Health-System Pharmacy. 63 (13): 1235–1243. doi:10.2146/ajhp050487. PMID 16790575.
- ^ World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
- ^ World Health Organization (2019). The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization. hdl:10665/330668. ISBN 9789241210300. ISSN 0512-3054. WHO technical report series;1021.
- ^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528.